http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108078956-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5169 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108078956-B |
| titleOfInvention | Pancreatic cancer targeted nucleic acid polypeptide nano-drug and preparation method thereof |
| abstract | The invention discloses a nucleic acid polypeptide nano-drug targeting pancreatic cancer and a preparation method thereof, wherein pancreatic cancer targeting polypeptide and miRNA are self-assembled to generate a nano-composite, which is divided into two parts, wherein one part is as follows: the chimeric peptide PL-1 is formed by fusing a pancreatic cancer specific polypeptide and the N-terminal of nine D-or L-arginine residues through a section of pancreatic cancer targeting polypeptide and four glycine linkers; II, secondly: the chimeric peptide PL-1 captures anionic miRNA through electrostatic interaction, and forms a nano-complex through self-assembly. The invention has the beneficial effects that: the in vivo and in vitro experiments show that the nanoparticles have specific targeting affinity for pancreatic cancer and can remarkably enhance the treatment effect of chemotherapeutic drugs, provide technical support and preclinical research evidence for clinically developing novel pancreatic cancer targeted drugs, generate targeted nano preparations by combining polypeptide and miRNA, and provide a new idea for researching and developing other tumor drugs. |
| priorityDate | 2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.